Overview

Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD)

Status:
Unknown status

Trial end date:
2013-06-01

Target enrollment:
0

Participant gender:
All

Summary

Pulmonary hypertension is frequently present in COPD and it is generally limited to a mild increase in mean pulmonary artery pressure. However some COPD patients are characterized by higher levels of mPAP at rest, fulfilling the definition of moderate or severe PH disproportionate PH . In these patients the elevated pulmonary pressures adversely affect the prognosis.At the present time the evidence for the the use of specific pulmonary vasodilators in the management of these patients are scarce and cannot be recommended.the aim of this study is to evaluate the medium term efficacy and safety of the inhaled prostacyclin stable analog, iloprost in patients with COPD and moderate to severe pulmonary hypertension

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Carmel Medical Center

Treatments:

Iloprost

Criteria

Inclusion Criteria:

1. Patient with COPD and increased SPAP >55 on echocardiogram will be screened for the
study.

2. Patients with normal wedge pressure ( [PCWP] ≤ 15 mm Hg), mean PAP ≥ 35 mm Hg and a
pulmonary vascular resistance (PVR- 3.0 wood unit)on right heart catheterization.

3. Diagnosis of COPD according to GOLD guidelines

4. The patient can read, understand and sign the informed consent.

Exclusion Criteria:

1. Other identified cause for pulmonary hypertension